60 Degrees Pharmaceuticals, Inc. (NasdaqCM: SXTP)
Health Care · Pharmaceuticals · US
$1.13
-5.44% today · -77.0% 1Y
60 Degrees Pharmaceuticals, Inc. (NasdaqCM: SXTP) operates in the Pharmaceuticals industry within the Health Care sector. The company is valued at $3.18M and employs 3 people.
Over the last twelve months the share price has lost 77.0%, trading between 1.05 and 8.62.
Tweenvest scores 60 Degrees Pharmaceuticals, Inc. across four factors: quality 26/100, value 53/100, growth 100/100. Its strongest factor is growth.
SXTP price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $3.18M
- Revenue (TTM)
- $1.21M
- P/E
- —
- EPS
- -5.41
- Dividend yield
- —
- Beta (5Y)
- 2.54
- 52-week high
- $8.62
- 52-week low
- $1.05
- Avg volume (3M)
- —
- Shares outstanding
- 2.66M
- Employees
- 3
- Next earnings
- —
About 60 Degrees Pharmaceuticals, Inc.
60 Degrees Pharmaceuticals, Inc. is a specialty pharmaceutical firm dedicated to developing and bringing to market therapies aimed at preventing and treating infectious diseases within the United States. The company currently offers Arakoda, an approved medication for malaria prophylaxis. Its pipeline includes several investigational drugs: Tafenoquine, in its 'Arakoda regimen' formulation, is undergoing Phase IIb clinical trials for potential use against COVID-19. Additionally, Tafenoquine is the subject of Phase IIA clinical studies for conditions such as babesiosis, fungal pneumonias, and candidiasis. Another candidate, Celgosivir, is being developed to address Zika, various respiratory viruses, and dengue fever. Further strengthening its development efforts, 60 Degrees Pharmaceuticals holds a patent license agreement with Tufts Medical Center, collaborating to advance Tafenoquine specifically for the treatment and prevention of babesiosis. The company was established in 2010 and maintains its corporate headquarters in Washington, D.C.
- Founded
- 2010
- Listed since
- Jul 12, 2023
- Exchange
- Nasdaq Capital Market
- Currency
- USD
Other Pharmaceuticals companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Eli Lilly and CompanyNYSE: LLY | $1.12T | $1,255.40 | +0.88% |
| Johnson & JohnsonNYSE: JNJ | $651.25B | $270.24 | +1.07% |
| Merck & Co., Inc.NYSE: MRK | $376.37B | $152.55 | +2.39% |
| Roche Holding AGSWX: ROP | $373.91B | CHF375.60 | +1.02% |
| Novartis AGSWX: NOVN | $302.17B | CHF127.42 | +0.85% |
| AstraZeneca PLCLSE: AZN | $258.76B | £122.40 | +1.26% |
| Novo Nordisk A/SCPSE: NOVO B | $207.84B | Dkr300.85 | +1.59% |
| Pfizer Inc.NYSE: PFE | $159.99B | $28.07 | +1.01% |
Figures last refreshed Aug 18, 2026.